FDA Approves ArkBio to Begin Phase II Trial for Novel Influenza Prevention Drug

The FDA has granted Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) clearance for its investigational new drug application for AK0406. This approval allows ArkBio to initiate a Phase II clinical trial in the U.S. for AK0406, a long-acting antiviral drug-Fc conjugate designed for influenza prevention in the general population. Preclinical data showed potent activity against both influenza A and B, potentially offering a new preventive option beyond existing vaccines.